薬物関連の重度の甲状腺機能低下症後のポマリドミド再暴露:症例報告

Francesca Bartolomei¹, Tommaso Za¹, Francesca Di Landro¹

¹Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.

Annals of hematology

|February 20, 2026

まとめ

多発性骨髄腫 (MM) に使用されるポマリドミドは,甲状腺機能低下を引き起こす可能性があります. 甲状腺機能のモニタリングが推奨され,ポマリドミドの再投与は,甲状腺機能低下症の治療後に安全です.

科学分野:

腫瘍学腫瘍学
エンドクリノロジーエンドクリノロジー
薬理学薬理学とは

背景:

ポマリドミドは,再発性耐性多発性骨髄腫 (MM) の効果的な経口療法です.
一般的に,高齢の患者でもよく耐えます.
薬剤による甲状腺機能低下症は,潜在的な有害な効果です.

研究の目的:

多発性骨髄腫患者のポマリドミドによって誘発された重度の甲状腺機能低下症の症例を報告する.
甲状腺機能低下症の治療後にポマリドミドを再投与する際の安全性を評価する.

主な方法:

ポマリドミドで治療された再発性/耐性MMの71歳の女性のケーススタディ.
治療前のおよび治療中の甲状腺機能のモニタリング.
甲状腺機能低下症のためにLevothyroxine療法を開始しました.
エウチロイド症を達成した後,ポマリドミドで再挑戦する.

主要な成果:

患者はポマリドミド治療中に重度の甲状腺機能低下を発症した.
レボチロキシン療法は彼女の症状を迅速に解消しました.
ポマリドミドによる再挑戦は安全で,甲状腺機能に悪影響はありませんでした.

結論:

ポマリドミドは,多発性骨髄腫患者で甲状腺機能低下を引き起こす可能性があります.
定期的な甲状腺機能検査は,ポマリドミド療法中に不可欠です.
ポマリドミドによるリチャレンジは,成功した甲状腺機能低下症の管理後に安全な選択肢です.

キーワード:

さらに関連する動画

04:14

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Published on: October 6, 2023

1.3K

04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K

関連する概念動画

01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

01:30

Drug Toxicity: Allergic Reactions

01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...

01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...

関連する実験動画